SCHEMBL5534769

SCHEMBL5534769

O=C(Cl)N1CC=C(c2ccc(Cl)cc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.59
LMNA P02545 2/20 0.54
MAPT P10636 2/20 0.54
HTT P42858 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
SIGMAR1 Q99720 9/20 0.52
CCR1 P32246 1/20 0.51
NAMPT P43490 1/20 0.50
QDPR P09417 1/20 0.49
SLC18A3 Q16572 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 2/20 0.47
NPC1 O15118 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
DRD2 P14416 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15556551 0.87 CNR1 (0.63) CNR1LMNAMAPTHTTNPSR1
SCHEMBL5547905 0.85 SIGMAR1 (0.49) CNR1LMNAMAPTHTTNPSR1
SCHEMBL5542441 0.85 ALDH1A1 (0.60) CNR1LMNAMAPTHTTNPSR1
SCHEMBL1193355 0.85 ALDH1A1 (0.63) CNR1LMNAMAPTHTTMEN1
SCHEMBL5538953 0.81 TRPV1 (0.47) CNR1LMNAMAPTHTTNPSR1
SCHEMBL5536529 0.81 QDPR (0.52) CNR1SIGMAR1NAMPTQDPRMEN1
SCHEMBL11087646 0.78 CNR1 (0.51) CNR1LMNAMAPTHTTNPSR1
SCHEMBL5543506 0.78 TRPV1 (0.47) CNR1LMNAMAPTHTTNPSR1
SCHEMBL349843 0.78 HSD11B1 (0.61) CNR1LMNAMAPTHTTNPSR1
SCHEMBL652961 0.78 NAMPT (0.60) CNR1CCR1NAMPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CNR1 857/4885LMNA 4152/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.